Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder

This study is currently recruiting participants.
Verified May 2013 by University of California, Los Angeles
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Joseph O'Neill, PhD, National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT00748761
First received: September 8, 2008
Last updated: May 24, 2013
Last verified: May 2013

September 8, 2008
May 24, 2013
June 2008
May 2013   (final data collection date for primary outcome measure)
Regional concentration of glutamate and glutamine in brain, as measured by Magnetic Resonance Spectroscopic Imaging (MRSI) [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
Regional concentration of glutamate and glutamine in brain, as measured by MRSI [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00748761 on ClinicalTrials.gov Archive Site
Overall score on child Yale-Brown Obsessive-Compulsive Scale [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder
Cognitive-Behavioral Therapy & Glutamatergic Neurometabolites in Pediatric OCD

This study will examine the way cognitive behavioral therapy changes the structure of the brain in patients with obsessive-compulsive disorder and will thereby determine what makes cognitive behavioral therapy an effective treatment.

Obsessive-compulsive disorder (OCD) afflicts 2% to 4% of children and adolescents, who suffer from persistent, unwanted thoughts and repetitive behaviors. One of the most effective treatments of OCD is cognitive behavioral therapy (CBT), yet researchers do not know how CBT affects the brain. In this study, brain scans will be performed to determine concentrations of several neurometabolites, which are chemicals involved in providing energy to the brain. Of particular importance are the neurometabolites glutamine and glutamate, which, in addition to providing energy to the brain, are among the most common excitatory neurotransmitters. Disruption of glutamine and glutamate is thought to be related to OCD. By examining where in the brain levels of glutamate and glutamine change, researchers will attempt to determine whether CBT modifies brain activity, whether a circuit targeted by researchers is affected by CBT, and how brain activity in people with OCD differs from that of people without the disorder in terms of the targeted circuit.

Children and adolescents ages 8 through 17 with OCD will be randomly assigned to either receive a 12-week CBT intervention or be placed on a waiting list for 8 weeks before receiving the 12-week intervention. A group of non-OCD participants in the same age group will be used as a control. All groups will undergo magnetic resonance spectroscopic imaging (MRSI), which will measure the concentrations of neurometabolites in multiple brain regions. The control group and the group initially given the CBT intervention will be scanned upon entry of the study and after 12 weeks. The group initially placed on a waiting list will be scanned three times: once upon entry, once after the 8-week waiting period, and once after the 12-week CBT intervention. To determine which participants are benefitting from the treatment, the Yale-Brown Obsessive-Compulsive Scale and other clinical and neurocognitive measures will be administered concurrently with each brain scan.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Obsessive-Compulsive Disorder
  • Behavioral: Cognitive Behavioral Therapy (CBT)
    Nondrug psychotherapy administered weekly for 12 weeks
    Other Names:
    • Behavioral therapy
    • Psychotherapy
    • Exposure and response prevention
  • Behavioral: Waitlist
    Contact waitlist weekly for 12 weeks
    Other Names:
    • Waiting for treatment
    • In line for treatment
  • Experimental: OCD Active CBT
    Children with obsessive-compulsive disorder (OCD) will be treated with cognitive behavioral therapy (CBT) from the time of enrollment.
    Intervention: Behavioral: Cognitive Behavioral Therapy (CBT)
  • Active Comparator: OCD Waitlist
    Children with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
    Interventions:
    • Behavioral: Cognitive Behavioral Therapy (CBT)
    • Behavioral: Waitlist
  • No Intervention: Healthy Controls
    Healthy control children will be given no intervention.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
108
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets DSM-IV diagnostic criteria for OCD as primary diagnosis, based on the Anxiety Disorders Interview Schedule (ADIS) Clinical Severity Rating
  • Clinical Global Impressions severity score of at least 4, reflecting moderately ill or worse status
  • Children's Yale-Brown Obsessive Compulsive Scale total score of greater than or equal to 16
  • No medication for OCD or other psychiatric condition in the past 4 weeks and no use of fluoxetine for the past 6 weeks
  • Child is fluent in English
  • Parental informed consent and child or adolescent informed assent forms are signed
  • For females of childbearing potential a negative pregnancy test will be required for study entry

Exclusion Criteria:

  • IQ of less than 80 on the Wechsler Abbreviated Scales of Intelligence
  • A lifetime DSM-IV diagnosis of pervasive developmental disorder, mania, psychosis, conduct disorder, or substance dependence assessed through ADIS
  • Current DSM-IV diagnosis of major depressive disorder or attention deficit hyperactivity disorder any subtype, assessed through an ADIS rating of 4 or higher
  • Any serious psychiatric, psychosocial, or neurological condition, such as a tic disorder, non-OCD anxiety, aggression, or family discord, that requires immediate treatment other than that provided in the current study
  • One or more failed adequate trials of exposure-based CBT, defined as at least 10 sessions of therapist-assisted, exposure-based CBT with which the patient voluntarily complied
  • More than one failed selective serotonin reuptake inhibitor trial adequate in dose and duration, defined as at least 8 weeks of treatment with at least 20 mg of fluoxetine, 20 mg of paroxetine, 75 mg of sertraline or fluvoxamine, or 75mg of clomipramine
  • Any body metal (other than dental fillings), pregnancy, or other contraindications to MRSI scan
Both
6 Years to 18 Years
Yes
Contact: John C. Piacentini, PhD 310-206-6649 jcp@ucla.edu
United States
 
NCT00748761
R01 MH081864, R01MH081864, DDTR B2-NDO
No
Joseph O'Neill, PhD, National Institute of Mental Health (NIMH)
University of California, Los Angeles
National Institute of Mental Health (NIMH)
Principal Investigator: Joseph O'Neill, PhD UCLA Child Psychiatry
Principal Investigator: John C. Piacentini, PhD UCLA Child Psychiatry
University of California, Los Angeles
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP